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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).SUMMARYTransplantation of glial-rich neural progenitors has been demonstrated to attenuatemotor neuron degeneration and disease progression
in rodent models of mutant superoxide dismutase 1 (SOD1)-mediated amyotrophic lateral sclerosis (ALS). However, translation of these
results into a clinical setting requires a renewable human cell source. Here, we derived glial-richneural progenitors fromhuman iPSCs and
transplanted them into the lumbar spinal cord of ALSmousemodels. The transplanted cells differentiated into astrocytes, and the treated
mouse group showed prolonged lifespan. Our data suggest a potential therapeutic mechanism via activation of AKT signal. The results
demonstrated the efficacy of cell therapy for ALS by the use of human iPSCs as cell source.INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a disorder of motor
neurons (MNs) that is characterized by their relatively rapid
degeneration, resulting in progressive muscle weakness
and respiratory failure (Bruijn et al., 2004). Approximately
90%–95% of ALS cases are sporadic in nature, with 20% of
the remaining familial cases linked to various point muta-
tions in the Cu/Zn superoxide dismutase 1 (SOD1) gene.
Transgenic mice and rats carrying ALS-associated mutant
human SOD1 genes (mSOD1) recapitulate many features
of the human disease (Gurney et al., 1994).
Despite the relative selectivity of MN loss in ALS, studies
in mSOD1 rodent and tissue culture models show non-
neuronal (glial) cell involvement in the disease process
(Boille´e et al., 2006; Yamanaka et al., 2008). Astrocytes in
particular are hypothesized to play a role in both mSOD1
and sporadic forms of ALS (Haidet-Phillips et al., 2011;
Howland et al., 2002; Papadeas et al., 2011). Regardless of
whether astrocyte dysfunction is a cause of the disease or
a consequence of neuronal death, altered astrocyte physi-
ology results in further susceptibility to MN loss (Boille´e
et al., 2006). Targeted enrichment of normal astrocytes in
mSOD1 rat spinal cord via intraspinal transplantation of
rodent glial-restricted progenitors promoted focal MN
protection, delayed decline in respiratory function, and
extended disease progression (Xu et al., 2011).242 Stem Cell Reports j Vol. 3 j 242–249 j August 12, 2014 j ª2014 The AutVarious kinds of cells have been investigated for trans-
plantation studies (Corti et al., 2004; Garbuzova-Davis
et al., 2008; Iwanami et al., 2005; Piccini et al., 1999).
Neuronal cells are probably the most relevant cell type for
ALS treatment, but such cells suffer from a limited supply,
ethical issues, and/or invasive harvest fromhuman donors.
On the other hand, human induced pluripotent stem cells
(hiPSCs) can be obtained from a donor less invasively and
can be expanded indefinitely in vitro. In this context,
here we established a differentiation protocol of glial-rich
neural progenitors (GRNPs) from hiPSCs and investigated
the potential of hiPSC-derived glial-rich neural progenitors
(hiPSC-GRNPs) as a cell source for intraspinal transplanta-
tion therapy of ALS.RESULTS
Cell Resource Establishment for Transplantation
As a cell resource, we selected human iPSC line ‘‘201B7
clone,’’ which had been previously evaluated as possessing
low tumorigenicity after transplantation therapy (Kobaya-
shi et al., 2012; Nori et al., 2011) To distinguish the
transplanted cells from host cells, we introduced a piggyBac
vector, which stably expresses GFP gene under the control
of the ubiquitous EF1a promoter, into hiPSCs and observed
continuous GFP fluorescence even after neural-lineagehors
Figure 1. Human iPSCs Were Labeled with GFP, and They Differentiated into Neural Precursors
(A) hiPSCs were labeled with GFP by a piggyBac vector.
(B) GFP-labeled hiPSCs retained GFP signals after neural induction.
(C) hiPSC-derived neural precursors exhibited immunoreactivities for NESTIN (neural precursor marker), GFAP (astroglial or radial-glial
marker), GLT1/ALDH1 (functional/mature astrocyte marker), A2B5/CNPasae (oligodendrocyte lineage marker), and TUJ1/MAP2 (neural
lineage marker).
(D) Quantification of hiPSC differentiation in (C).
Data represent mean ± SD (n = 3 experiments). Scale bars, 200 mm.
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labeled hiPSCs into neural stem cells by the serum-free
floating culture of embryoid bodies-like aggregates method
with SMAD-pathway inhibition (Kondo et al., 2013).
Neural stem cells were efficiently differentiated into
hiPSC-GRNPs by stimulation of the LIF/BMP signaling.
This protocol provided highly enriched neural precursors,
68.4% ± 7.2% positive for NESTIN and 54.9% ± 6.1%
positive for GFAP (Figures 1C and 1D). At day 16 in vitro,
most of the differentiated grafts were positive for NESTIN
or GFAP. At this very early stage, GFAP+ cells include either
radial glia, a subtype of developmental neural progenitors
with a neuron-like spine, or immature astrocytes (Liour
and Yu, 2003). At day 28 in vitro, NESTIN+ neural progen-
itors differentiated into TUJ1+ neurons, A2B5+ oligoproge-
nitors, and GFAP+ astrocytes. The differentiation method
used in the present work could augment the GFAP+ glial
population and attenuate TUJ1 neural differentiation, as
compared with our previous method (Kondo et al., 2013).Stem CHowever, GFAP+ astrocytes were not positive for GLT1 or
ALDH1L1, which were thought to be functionally mature
astrocytes before transplantation.
hiPSC-GRNPs Transplantation Improved Motor
Function and Survival in ALS Model Mice
All animal experiments were approved by the CiRA Animal
Experiment Committee (nos. 24 and 27). We transplanted
40,000 hiPSC-derived GRNPs each into bilateral lumbar
spinal cords of transgenic SOD1-G93A mice. Transplanta-
tion operations were performed after onset of ALS pheno-
type, at 90 days of age to mimic the clinical situation
(Figure 2A). Littermates of transplanted mice received
only a vehicle (PBS) injection and were used as control
group. We designed the study so that siblings were distrib-
uted equally in the control (n = 24, male:female = 17:7) and
transplanted (n = 24,male:female = 17:7) groups. By using a
35 gauge needle and a relatively small injection volume, we
could avoid motor disturbance at 24 hr after the surgicalell Reports j Vol. 3 j 242–249 j August 12, 2014 j ª2014 The Authors 243
Figure 2. hiPSC-GRNPs Transplantation Improved Motor Score and Survival in ALS Model Mice
(A) Transplantation schedule and schema of spinal cord injection site. Transplantation was performed after disease onset.
(B) Mice presented with no side effects after transplantation and made vigorous twisting movements with hind-limb extension, as shown
by representative photos at tail suspension. Both groups showed no change in motor clinical score at 24 hr after surgical insult.
(C) Clinical motor scoring change by sequential evaluation showed significant difference from 100 to 120 days after birth (*p < 0.05). Data
represent mean ± SEM (n = 21 mice per group).
(D) Lifespan was prolonged in the hiPSC-GRNPs transplantation group (162.2 ± 12.8 days) compared to the control group (150.4 ±
12.1 days) (**p < 0.01). Data represent mean ± SD (n = 21 mice per group).
(E) Survival (Kaplan-Meier plot) analysis shows a significant difference between the PBS injection group survival (black line) and the
hiPSC-GRNPs transplantation group survival (green line) throughout the course of the study (n = 21 mice per group, p = 0.00691 stratified
log-rank test), suggesting that the hiPSC-GRNPs transplantation group had better survival (**p < 0.01).
(F) The number of axons in L4 ventral nerve root was counted to estimate surviving motor neurons at the middle stage of disease pro-
gression. At 120 days after birth, transverse sections of ventral nerve roots were stained with an anti-neurofilament-H antibody. Compared
to littermates without transgene, the number of axons in Tg SOD1-G93A mice was decreased. Each axon caliber was measured and classified
according to size.
(G) Cumulative axon caliber distribution at L4 ventral root at 120 days after birth of both groups. Two-way ANOVA with repeated-measures
was used to study the effect of transplantation (transplanted and nontransplanted mice) on axonal caliber distribution. Pairwise
(legend continued on next page)
244 Stem Cell Reports j Vol. 3 j 242–249 j August 12, 2014 j ª2014 The Authors
Stem Cell Reports
Transplantation for ALS Mice Using Human iPSCs
Figure 3. Transplanted Cells Differentiated Mainly into Astrocytes
(A) Transplanted GFP-labeled grafts (green) survived in the spinal cord. Scale bars, 500 mm.
(B) Most of the GFP-labeled grafts in ventral horn parenchyma differentiated into mature astrocytes, which were positive for astrocyte
markers (red), including GFAP, ALDH1L1, and GLT1, in vivo. A relatively small population of grafts also differentiated into CNPase+
oligodendrocytes or MAP2+ neurons. A limited number of grafts remained as NESTIN+ neural progenitors. Scale bar, 50 mm.
(C) Quantification of positive ratio of cell type markers in (B). A small number of GFP-labeled grafts were also positive for A2B5, an
oligoprogenitor marker, MAP2, a neuronal marker, or Nestin, a neural precursor marker, in vivo. The total number of GFP-positive cells,
counted to calculate the positive ratio, was 113.3 ± 14.7 for NESTIN, 75.9 ± 11.8 for GFAP, 68.7 ± 5.5 for GLT1, 76.9 ± 9.4 for ALDH1L1,
67.3 ± 13.0 for A2B5, 69.3 ± 19.2 for CNPase, 70 ± 13.6 for TUJ1, and 66.7 ± 20.2 for MAP2, respectively. Data represent mean ± SD (n = 3
mice per group). See also Figure S2.
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Transplantation for ALS Mice Using Human iPSCsinsult (Figure 2B), evaluated by clinical grading system
(Table S1 available online).
At 10–40 days after the procedure, we observed improve-
ment in clinical motor score in the hiPSC-GRNPs trans-
plantation group (Figure 2C). Surviving lifespan was
extended by 7.8% in the hiPSC-GRNPs transplantation
group (n = 21, male:female = 14:7, 162.2 ± 12.8 days)
compared to the control group (n = 21, male:female =
14:7, 150.4 ± 12.1 days) (Figures 2D and 2E). When the
effect of transplantation was evaluated separately in male
and femalemice, a greater survival improvementwas noted
in males than in females (Figure S1). Survival lifespan was
significantly expanded only in males (145.3 ± 9.8 days
for control, 158.5 ± 11.2 days for the hiPSC-GRNPs trans-
plantation group, extended by 9.1%), not in females
(160.5 ± 9.5 days for control, 169.7 ± 12.6 days for the
hiPSC-GRNPs transplantation group, extended by 5.7%).
To evaluate motor neuron degeneration at the symptom-
atic phase, threemalemice from each groupwere sacrificedcomparisons were made using Bonferroni adjustment (*p < 0.05). The
number of 6–8 mm caliber axons was significantly increased in the hi
mice per group).
Scale bars, 100 mm. hiPSCs, human induced pluripotent stem cells;
Figure S1 and Table S1.
Stem Cat 120 days of age. The number of 6–8 mm large-caliber
fibers was increased in the hiPSC-GRNPs transplantation
group (Figures 2F and 2G).We could not detect GFP signals,
derived from transplanted hiPSC-GRNPs, in nerve root
slices.
Transplanted hiPSC-GRNPs Differentiated into
Astrocytes in Spinal Cord of ALS Model Mice without
Tumorigenic Formation
Wecontinued to evaluate clinicalmotor function (Table S1)
and defined clinical grade 0 as end stage. At the end stage of
disease progression, around 140–170 days after birth, the
animals were sacrificed and histological analysis was per-
formed to investigate the state of the engraftment. Trans-
planted hiPSC-GRNP-derived cells, which are positive for
GFP signals, continued to survive in the lumbar spinal
cord of ALS model mice (Figure 3A). Engraftment could be
observed at least 5 mm away from the injection site. We
assessed some cell subtype markers by immunostaining,number of 1–2 mm caliber axons was significantly decreased and the
PSC-GRNPs transplantation group. Data represent mean ± SD (n = 3
hiPSC-GRNPs, hiPSC-derived glial-rich neural progenitors. See also
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Figure 4. hiPSC-GRNPs Transplantation Increased Neurotrophic Factors and Activated AKT Signal
(A) Gene expressions of neurotrophic factors, including Vegf, Ngf, Nt3, Bdnf, Gdnf, and Hgf were quantitatively analyzed using mouse-
specific primers. The levels of Vegf, Nt3, and Gdnf were significantly increased in the hiPSC-GRNPs transplantation group (*p < 0.05). Data
represent mean ± SD (n = 3 mice per group).
(B) Gene expressions of neurotrophic factors, including VEGF, NGF, NT3, BDNF, GDNF, and HGF were quantitatively analyzed
using human-specific primers and the human-origin/mouse-origin ratio was calculated. Data represent mean ± SD (n = 3 mice per
group).
(C) Western blot analysis of phosphorylated AKT, total AKT level, and VEGF in lumbar spinal cord in the PBS injection group and hiPSC-
GRNPs transplantation group.
(D) Densitometric analysis of (C). Measured values of proteins were normalized by that of b-actin. The levels of VEGF and AKT phos-
phorylation were significantly increased in the hiPSC-GRNPs transplantation group (*p < 0.05).
Data represent mean ± SD (n = 5 mice per group). N.D., not detectable. See also Figure S3 and Table S2.
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A2B5 for oligodendroglial progenitors, and NESTIN for
neural progenitors (Figure 3C). Around 60%–80% of the
cells at the grafts were double-positive for GFP fluorescence
and GFAP marker, suggesting that transplanted hiPSC-
GRNPs had differentiated into astrocytes (Figure 3C).
Although we hardly observed the immunoreactivity of
functional/mature astrocyte markers including GLT1 and
ALDH1L1 in vitro before transplantation, we did observe
it after transplantation. The rate of neurons or oligoden-
drocytes was low (Figure 3C). Only a small population
of grafts retained positive staining for NESTIN, that is, re-
maining in the neural progenitor stage of differentiation
(Figure 3C).
It is important to note that, during our observation
period (up to 3 months posttransplantation), the injection
sites showed no signs of tumor formation. Gross patholog-
ical examinations of other organs outside the CNS did not
reveal any heterotopic engraftment.246 Stem Cell Reports j Vol. 3 j 242–249 j August 12, 2014 j ª2014 The AutTransplanted hiPSC-GRNPs Upregulated
Neurotrophic Factors and Activated Cell Survival
Signal
We investigated the expression level of neurotrophic
factors in lumbar spinal cord. We designed mouse- or
human-specific primers to evaluate host- or graft-derived
mRNA separately (Table S2). Quantitative RT-PCR revealed
that upregulated expressions were observed in mouse
(host)-originated Vegf, Nt3, and Gdnf, but not in Ngf,
Bdnf, or Hgf (Figure 4A). However, human (graft)-origi-
nated expression, equal to hiPSC-GRNPs origin, was
observed only in VEGF (Figure 4B). Western blot analysis
demonstrated a significant increase in VEGF level in the
hiPSC-GRNPs transplantation group (Figures 4C and 4D).
Furthermore, hiPSC-GRNPs transplantation increased
phosphorylated AKT and activated AKT signaling, which
is downstream from the VEGF signal and is important
for cell survival in ALS (Lunn et al., 2009) (Figures 4C
and 4D).hors
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Here, we describe that transplantation of human iPSC-
derived GRNPs produced astrocytes in vivo and prolonged
the survival period of mSOD1mice. We used hiPSC-GRNPs
for testing the efficacy in mSOD1 mice, because replace-
ment therapy using astrocytes from rodent glial-restricted
progenitors in the cervical spinal cord of ALS rodent
models is already well established (Xu et al., 2011).
We showed that glial cells represent a potential target of
ALS therapy. However, we observed transient improve-
ment of lower limb function, as shown in Figure 2C,
and a similar previous study failed to show improvement
in the rescue of clinical manifestations and neuronal sur-
vival by transplantation of human-derived glial-restricted
progenitor cells from 17- to 24-week fetus into SOD1
transgenic mouse spinal cord despite the survival and pro-
liferation of exogenous astrocytes (Lepore et al., 2011).
Although the transient improvement in our study might
have stemmed from neuroprotective effects of the trans-
planted cells only in the lumbar region, with a possible
broader effect of neurotrophic factors on other regions
or behavioral alteration for food intake, as previously dis-
cussed (Table S1), we comprehensively compared the two
studies as well as others regarding lumbar transplantation
in terms of a number of aspects (Table S1), speculating
that there were differences in graft type, transplantation
condition, and/or transplantation timing. Regarding the
timing of transplantation, the survival improvement
in our study might have resulted in attenuation of the
glial contribution to the disease pathogenesis at an early
symptomatic stage (Boille´e et al., 2006; Yamanaka et al.,
2008). Regarding the cell injection site, instead of the cer-
vical cord, we injected the cells into the lumbar spinal
cords of ALS model mice, which resulted in improved
clinical scores of lower limbs. These data supported the
possibility of targeting not only the cervical cord but
also the lumbar spinal cord in ALS clinical trials, depend-
ing on the symptoms to be treated. Following previous
transplantation research (Table S1), we selected PBS,
which is a vehicle solution for grafts, as control agent of
transplantation. Dead cells or fibroblasts can be ap-
propriate control agents but may also possibly secrete
various factors. Furthermore, previously an extensive
study showed that, as a control agent, there was no signif-
icant difference among vehicle solution, dead cells, and
fibroblasts (Lepore et al., 2008).
iPSCs were previously reported to induce T cell-depen-
dent immune response by direct transplantation of un-
differentiated cells into syngeneic mice. However, a more
detailed investigation proved that autologous transplanta-
tion of terminally differentiated cells derived from iPSCs or
embryonic stem cells elicits only negligible immunoge-Stem Cnicity (Araki et al., 2013; Okano et al., 2013). In our study,
we did not observe excess inflammatory responses around
transplanted cells under treatment of low-dose immuno-
suppression, suggesting that even if transplanted cells
were not autologous, we could control the immune
responses of the recipients by immunosuppressant
treatment.
The increase in the levels of neurotrophic factors had
been commonly observed in transplantation therapy of
ALS models (Nizzardo et al., 2014; Teng et al., 2012). We
observed that the transplanted hiPSC-GRNPs produced
VEGF, and expressions of endogenous VEGF and other
neurotrophic factors in the host mice were upregulated. A
previous study showed that VEGF retrograde delivery
with lentiviral vector could prolong the survival of ALS
model mice by 30% (Azzouz et al., 2004) and that activated
AKT signaling, which is downstream of VEGF, is important
for cell survival in ALS (Lunn et al., 2009). Similarly in this
study, transplanted hiPSC-GRNPs increased the VEGF
level and prolonged the survival of mSOD1 mice. We
could observe positive immunostaining for VEGF and
phosphorylated AKT in both remaining motor neurons
and astrocytes. However, we could not observe any
morphological difference in motor neurons between con-
trol and transplanted groups at end-stage. We also specu-
lated that, as shown in previous studies (Howland et al.,
2002), transplanted hiPSC-GRNPs differentiated into astro-
cytes expressing glutamate transporter 1 (GLT1) might
restore glutamate homeostasis in our study.
In our study, the males in both the control and hiPSC-
GRNPs transplantation groups died long before the
females, and this result is consistent with the previous
reports of ALS model mice (Cervetto et al., 2013; Choi
et al., 2008). However, improvement in male mice was
greater than in females (Figure S1) Interestingly, a similar
gender-dependent difference of therapeutic efficacy was re-
ported in ALS model mice (Cervetto et al., 2013; Li et al.,
2012). The epidemiological studies of sporadic ALS have
shown that both incidence and prevalence of ALS are
greater in men than in women and onset of the disease is
also earlier for men than it is for women (McCombe and
Henderson, 2010). Sex steroids are suggested to be involved
in the gender difference in ALS, but the direct importance
of estrogen is still controversial (Choi et al., 2008; Li
et al., 2012). Moreover, male neural cells are reported to
be more vulnerable to oxidative stress, induced by mutant
SOD1 overexpression, than female neural cells (Li et al.,
2012). In our study, transplanted cells were mainly differ-
entiated into GFAP-positive astrocytes and upregulated
VEGF. Furthermore, astrocytes can play neuroprotective
roles from oxidative stress via VEGF (Chu et al., 2010).
These findings suggest that hiPSC-GRNPs transplantation
may ameliorate male-specific vulnerability to oxidativeell Reports j Vol. 3 j 242–249 j August 12, 2014 j ª2014 The Authors 247
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Further analysis would be necessary to elucidate VEGF-
associated mechanisms in transplantation therapy.
In regard to safety, the potential tumorigenicity of grafts
is a predominant concern. We used the human iPSC line
‘‘201B7,’’ which was previously reported to be safe from
the viewpoint of tumorigenesis (Kobayashi et al., 2012).
Furthermore, we found no signs of tumor formation or
Ki67-positive grafts (Figure S2). However, a very small
proportion of grafts remained positive for the neural
progenitor marker NESTIN at 3 months posttransplanta-
tion. We cannot exclude the risk of tumor formation
from the remaining NESTIN-positive NPCs. It is important
to evaluate tumorigenicity by longer-term observations for
future clinical trials.
We tested the potential of cell therapy after onset of
the disease in ALS model mice, because most human cases
of ALS are sporadic and any treatment would be initiated
after onset. Our study showed a modest lifespan prolonga-
tioncompared toprevious studies testing cell therapybefore
diseaseonset inALSmodelmice. Future studiesof transplan-
tations, suchas combinationswithMNengraftment,will be
required to accelerate ALS treatment toward restoration of
MN function and ultimately the complete cure of ALS.EXPERIMENTAL PROCEDURES
Preparation of hiPSC-GRNPs for Transplantation
We differentiated hiPSCs into neural lineage cells using a previ-
ously described differentiation protocol (Kondo et al., 2013), under
the condition of additional 10 ng/ml human BMP4 (R&D Systems)
and 10 ng/ml human LIF (R&D) during the patterning stage (days
8–28).Transplantation
We transplanted 40,000 hiPSC-GRNPs into bilateral lumbar spinal
cords of 90-day-old Tg SOD1-G93Amice. Eachmouse received two
grafts (bilaterally at L3-L4) of 4 3 104 cells (in 0.5 ml PBS) into the
ventral horn.Statistical Analysis
The Mann-Whitney test was used for the analysis of two popula-
tions of means, and p values <0.05 were considered significant.
Repeated-measures two-way ANOVA, followed by the Tukey-
Kramer test, was used for clinical motor scoring analysis. The
Kaplan-Meier plot was used to evaluate survival time, and the
log-rank test was applied to compare cumulative curves.
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